COMMUNIQUÉS West-GlobeNewswire

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
20/11/2024
— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and front-line combo therapy [...]
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20/11/2024
REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on November 17, 2024, the Compensation Committee of Adverum’s Board of Directors granted an [...]
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
20/11/2024
Daix (France), Long Island City (New York, United States), November 20, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule [...]
Assemblée Générale Mixte du 11 décembre 2024 - Modalités de mise à disposition des documents préparatoires
20/11/2024
Daix (France), Long Island City (New York, Etats-Unis), le 20 novembre 2024 – Inventiva (Euronext Paris et Nasdaq : IVA), société́ biopharmaceutique spécialisée dans le développement clinique de petites molécules [...]
Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024
20/11/2024
Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www.inventivapharma.com Date Number of Shares Outstanding Total voting rights, gross (1) Total [...]
Information relative au nombre total de droits de vote et d’actions composant le capital social au 4 novembre 2024
20/11/2024
Article R. 22-10-23 du Code de commerce Place de cotation : Euronext Paris Code ISIN / Mnémo : FR0013233012 / IVA Site web : www.inventivapharma.com Date Nombre de titres composant le capital en circulation Nombre total [...]
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
20/11/2024
The PRIME initiative provides enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation Pivotal trials of NX-5948 are planned to initiate in 2025 SAN FRANCISCO, Nov. [...]
LAPIX Therapeutics Announces Positive Topline Phase 1 Clinical Data Results with LPX-TI641 for the Treatment of Autoimmune Diseases
20/11/2024
LPX- TI641 is an oral novel Treg-expanding T cell/transmembrane, immunoglobulin, and mucin (Tim)receptor agonist therapy in development for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriatic [...]
Court Filing against the Biden Administration’s Censorship Activities by the Association of American Physicians and Surgeons Educational Foundation Supports Its Expanded Allegations of Wrongdoing by the Federal Government
20/11/2024
TUCSON, Ariz., Nov. 20, 2024 (GLOBE NEWSWIRE) -- The Association of American Physicians and Surgeons Educational Foundation (“AAPS”) filed its reply in support of adding allegations against the censorship activities of [...]
MAPS Successfully Clears Path for Cannabis Research through FDA Formal Dispute
20/11/2024
After three years of negotiation with the FDA, MAPS has successfully secured FDA clearance to conduct a clinical trial, MJP2, to examine the use of smoked cannabis for the treatment of PTSD symptoms among ~320 Veterans [...]
Guerbet annonce le lancement commercial en France d’Elucirem® (Gadopiclenol) son nouveau produit de contraste pour les examens d’imagerie par résonance magnétique (IRM).
20/11/2024
Guerbet annonce le lancement commercial en France d’Elucirem ® (Gadopiclenol) son nouveau produit de contraste pour les examens d’imagerie par résonance magnétique (IRM). Villepinte, le 20 novembre 2024 : Guerbet ( [...]
VITAS® Healthcare Honors Retired Hospice Veteran, Announces New Executive Leadership
20/11/2024
MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) -- VITAS Healthcare, the nation’s leading provider of end-of-life care and a best-in-class healthcare employer , proudly announces four major executive leadership changes: Bob [...]
Information relative au nombre total de droits de vote et d’actions composant le capital social
20/11/2024
Communiqué de Presse Dijon, le 20 novembre 2024 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de médicaments dédiés aux situations d’ [...]
Trading by management and close relations of management
20/11/2024
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of [...]
Sotera Health to Share Next Chapter of Growth at 2024 Investor Day
20/11/2024
CLEVELAND, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare [...]
Zarminali Health Launches with $40M in Seed Funding to Transform Pediatric Care through Nationwide, Multi-specialty Practice Group
20/11/2024
New model for outpatient pediatric care combines seamlessly coordinated primary and specialty care with cutting-edge technology to transform the patient and family experience, and address physician burnout CHICAGO, Nov [...]
PeopleOne Health and RosenCare Celebrate Opening of Fourth Health Center in Central Florida
20/11/2024
New Orlando facility advances the team’s mission of transforming healthcare in Florida, improving access to quality health and wellness services ORLANDO, Fla. and PITTSBURGH, Nov. 20, 2024 (GLOBE NEWSWIRE) -- PeopleOne [...]
CirrusMD Receives FedRAMP® Moderate Authorization for Virtual Care Solution
20/11/2024
Authorization demonstrates CirrusMD's commitment to securely serving Veterans with Virtual Health Chat for Government DENVER, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CirrusMD, creator of the Physician-first Care & [...]
KOELIS announces the first interim results of the VIOLETTE trial which evaluates the use of OBT-Fusion® technology in focal ablation of the prostate by microwave needles
20/11/2024
GRENOBLE, France, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com ), a global leader and innovator in prostate care, announced today passing an important milestone demonstrating [...]

Pages